GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Citius Pharmaceuticals CTXR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.53

-3.45%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Citius Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Citius Pharmaceuticals is based in Cranford, New Jersey and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CTXR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2022, it reported revenue of $90,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Aug 2017
Employees
23
Head office
11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Leonard MazurExecutive Chairman of the Board, Chief Executive Officer, Company Secretary, since 2014$3.5m
  • Mr. Myron HolubiakExecutive Vice Chairman of the Board, since 2015$2.2m
  • Mr. Jaime BartushakChief Financial Officer, Chief Business Officer$1.7m
  • Dr. Myron CzuczmanChief Medical Officer, Executive Vice President$1.2m
  • Mr. Suren DutiaIndependent Director$293,555
  • Dr. Eugene HolukaIndependent Director$274,055
  • Mr. Dennis McgrathIndependent Director$306,269
  • Mr. Robert SmithIndependent Director$48,424
  • Ms. Carol WebbIndependent Director$270,731
  • Ms. Ilanit AllenVice President - Corporate Communications and Investor Relations

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
25
Environment
28
Social
19
Governance
27
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Citius Pharmaceuticals focuses on critical care products in the Health Care sector.
  • The company employs 23 staff members to support its specialized operations.
  • Mino-Lok treats catheter-related bloodstream infections without removing central venous catheters.

Weaknesses

  • The firm currently employs only 1 full-time employee for operations.
  • Citius Pharmaceuticals is headquartered in Cranford, New Jersey, limiting local talent.
  • The company went public on 3 August 2017, having a short history.

Opportunities

  • CITI-002 provides symptomatic relief for hemorrhoids using halobetasol and lidocaine.
  • Mino-Wrap reduces inflammation in breast tissue expanders during reconstruction surgeries.
  • CITI-101 represents another product candidate for the company's pipeline development.

Threats

  • The pharmaceutical industry faces strict regulatory requirements for anti-infective products.
  • Citius Pharmaceuticals relies on three specific product candidates for future revenue.
  • Competitors in the Health Care sector may develop similar critical care solutions.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.